Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 980 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Symptomatic Clear all
Recruiting Phase 2 Interventional

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

NCT07104331
View directory record Official record
Conditions
Epithelioid Hemangioendothelioma (EHE)
Interventions
nab-Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 6, 2026, 7:42 AM EDT
Recruiting Phase 2 Interventional

Spine Radiosurgery for Symptomatic Metastatic Neoplasms

NCT05617716
View directory record Official record
Conditions
Metastatic Neoplasm to the Spine, Metastatic Neoplasm
Interventions
Conventional external beam radiation therapy dose (EBRT), Spine radiosurgery/stereotactic body radiation therapy standard dose, Spine radiosurgery/stereotactic body radiation therapy high dose
Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

NCT04540406
View directory record Official record
Conditions
Suspected or Confirmed COVID-19
Interventions
NBT-NM108, Usual Care Only
Drug · Other
Lead sponsor
Notitia Biotechnologies Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 6, 2026, 7:42 AM EDT
Not listed Phase 2 Interventional

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

NCT01455935
View directory record Official record
Conditions
Stroke
Interventions
Anti-platelets and statin, alteplase, intra arterial intervention
Drug · Procedure
Lead sponsor
Jacobs Neurological Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

NCT00558259
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Results available

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

NCT01258387
View directory record Official record
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 6, 2026, 7:42 AM EDT
Not listed Not applicable Interventional

Physiologic Pacing for Symptomatic First-Degree Heart Block

NCT06245304
View directory record Official record
Conditions
Symptomatic First-degree Heart Block
Interventions
Dual chamber Medtronic pacemaker implantation., DDD-50 pacing program, AAI-DDD 50 pacing program
Device · Other
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke

NCT00924638
View directory record Official record
Conditions
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Interventions
Reveal® XT Insertable Cardiac Monitor
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
40 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
19
States / cities
Mountain View, California • Denver, Colorado • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 6, 2026, 7:42 AM EDT
Completed No phase listed Observational

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

NCT00001448
View directory record Official record
Conditions
Candidiasis, Oral, Eating Disorders, HIV Infections, Speech Disorders
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 7:42 AM EDT
Completed No phase listed Observational Results available

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

NCT01585961
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal Arrhythmia
Interventions
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis

NCT00303056
View directory record Official record
Conditions
Joint Disease
Interventions
HOE140 Icatibant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 6, 2026, 7:42 AM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

NCT04418024
View directory record Official record
Conditions
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Interventions
AG10, Placebo
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Not applicable Interventional Results available

CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

NCT01984346
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax, Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients

NCT00675103
View directory record Official record
Conditions
Chronic Gout Refractory to Conventional Therapy
Interventions
pegloticase 8 mg i.v.
Drug
Lead sponsor
Savient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • Wheaton, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 6, 2026, 7:42 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 6, 2026, 7:42 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT07105111
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Bryant, Arkansas • Chino, California • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 6, 2026, 7:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treatment Optimization of Brain-injured Warfighters

NCT06561100
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Sub-symptomatic Adaptable Exercise Treatment (SAET), Stretching Control Group (SCG)
Behavioral
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Camp Pendleton, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT05882812
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Not applicable Interventional Results available

Cerebral Protection in Transcatheter Aortic Valve Replacement

NCT02214277
View directory record Official record
Conditions
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Interventions
Cerebral Protection System-The SENTINEL System with TAVR, TAVR
Device
Lead sponsor
Claret Medical
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

NCT00690430
View directory record Official record
Conditions
Symptomatic Refractory Resistant Carcinoid Disease
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Phase 1 Interventional

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

NCT00263237
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 7:42 AM EDT
Completed Early Phase 1 Interventional Results available

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

NCT02849639
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, Medication Therapy Management (MTM), Scopolamine patch
Other · Drug
Lead sponsor
Daniela Moga
Other
Eligibility
65 Years to 101 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 6, 2026, 7:42 AM EDT